Table 1 Comparison of categorical variables in survivors and non-survivors

Sex

0.851†

 Females

24 (44.4%)

15 (45.5%)

9 (42.9%)

 Males

30 (55.6%)

18 (54.5%)

12 (57.1%)

Comorbidity

 Chronic kidney disease

10 (18.5%)

7 (21.2%)

3 (14.3%)

0.723‡

 Chronic liver disease

2 (3.7%)

0 (0.0%)

2 (9.5%)

0.147‡

 Hematological malignancy

2 (3.7%)

0 (0.0%)

2 (9.5%)

0.147‡

 History of thromboembolism

9 (17.0%)

6 (18.2%)

3 (15.0%)

1.000‡

 Diabetes mellitus

52 (96.3%)

33 (100.0%)

19 (90.5%)

0.147‡

The onset of diabetes mellitus

0.694‡

 Newly diagnosed

8 (15.4%)

6 (18.2%)

2 (10.5%)

 Previously diagnosed

44 (84.6%)

27 (81.8%)

17 (89.5%)

Glycemic control

 Diabetic ketoacidosis event

34 (63.0%)

21 (63.6%)

13 (61.9%)

0.898†

 Poor glycemic control in hospital

17 (31.5%)

9 (27.3%)

8 (38.1%)

0.404†

COVID-19 PCR positivity

0.653†

Recent within 2 weeks

20 (37.0%)

13 (39.4%)

7 (33.3%)

Previous within 2 months

34 (63.0%)

20 (60.6%)

14 (66.7%)

Implicated pathogen

0.329‡

 Mucoraceae

42 (77.8%)

24 (72.7%)

18 (85.7%)

 Aspergillus

12 (22.2%)

9 (27.3%)

3 (14.3%)

Extent of disease

 Sinonasal tissue infarction

54 (100.0%)

33 (100.0%)

21 (100.0%)

NA

 Skin infarction

25 (46.3%)

15 (45.5%)

10 (47.6%)

0.876†

 Intraorbital extension

38 (70.4%)

20 (60.6%)

18 (85.7%)

0.049†

 Intracranial extension

22 (40.7%)

10 (30.3%)

12 (57.1%)

0.050†

Severity of pulmonary affection

0.796§

 No lung affection

7 (13.0%)

5 (15.2%)

2 (9.5%)

 Mild

22 (40.7%)

13 (39.4%)

9 (42.9%)

 Moderate

7 (13.0%)

4 (12.1%)

3 (14.3%)

 Severe

18 (33.3%)

11 (33.3%)

7 (33.3%)

Debridement technique

All debrided patients (n = 52)

Survived (n = 32)

Died (n = 20)

0.606†

 Endoscopic

19/52 (36.5%)

10/32 (31.25%)

9/20 (45.0%)

 Combined endoscopic and external

33/52 (63.5%)

22/32 (68.75%)

11/20 (55.0%)